glp-1 medications market 2025 Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 GLP-1 Analogues Market Size, Share

I was quoted $1500 for a package of treatments

Dysesthesia The TRIUMPH-4 trial data revealed a notable safety signal: dysesthesia (abnormal sensations like tingling, burning, or numbness) was reported in 8.8% of participants on the 9 mg dose and 20.9% on the 12 mg dose of retatrutide

These large-scale, randomised controlled trials evaluated liraglutide 3.0 mg in adults with obesity or overweight, with follow-up periods extending to 56 weeks or longer

Respiratory Tissue Repair and Protection COPD fibroblast restoration occurs at 10 nanomolar concentration, restoring lung fibroblasts ability to contract and restructure collagen while elevating integrin beta 1 expression